Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel-bevacizumab in Advanced Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 2nd or 3rd line of non squamous non small cell lung cancer of stage III or IV~* Document progression at the time of the inclusion. At least, one previous chemotherapy line with platinum. Patient who had previous treatment with bevacizumab can be included.~* Patient with active mutation of EGFR must have had on line of chemotherapy with platinum and one with Tyrosine kinase inhibitor of EGFR.~* Patient with ALK rearrangement must have had at least one line of chemotherapy with platinum and one with crizotinib.~Exclusion Criteria:~* Mixed cancer small cells and non small cells or squamous lung cancer.~* Central nervous system symptomatic metastasis or requiring immediate cerebral radiotherapy~* patient who have had previous treatment with taxane (docetaxel, paclitaxel). Peri-operatory chemotherapy or chemoradiotherapy with taxane allowed if stopped more than 6 months before.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Docetaxel (Type: ACTIVE_COMPARATOR): None
- Paclitaxel - Bevacizumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).